Your browser doesn't support javascript.
loading
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss.
Lee, John; Fernandez, Katharine; Cunningham, Lisa L.
Afiliação
  • Lee J; Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA; email: cunninghamll@mail.nih.gov.
  • Fernandez K; Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA; email: cunninghamll@mail.nih.gov.
  • Cunningham LL; Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA; email: cunninghamll@mail.nih.gov.
Annu Rev Pharmacol Toxicol ; 64: 211-230, 2024 Jan 23.
Article em En | MEDLINE | ID: mdl-37562496
ABSTRACT
Each year over half a million people experience permanent hearing loss caused by treatment with therapeutic drugs with ototoxic side effects. There is a major unmet clinical need for therapies that protect against this hearing loss without reducing the therapeutic efficacy of these lifesaving drugs. At least 17 clinical trials evaluating 10 therapeutics are currently underway for therapies aimed at preventing aminoglycoside- and/or cisplatin-induced ototoxicity. This review describes the preclinical and clinical development of each of these approaches, provides updates on the status of ongoing trials, and highlights the importance of appropriate outcome measures in trial design and the value of reporting criteria in the dissemination of results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Perda Auditiva Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Perda Auditiva Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article